Effects of an Epithelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Add-on in Stereotactic Radiosurgery for Brain Metastases Originating from Non-Small-Cell Lung Cancer
Hyun Jung Kim, Woo Sung Kim, Do Hoon Kwon, Young Hyun Cho, Chang-Min Choi
J Korean Neurosurg Soc. 2015;58(3):205-210.   Published online 2015 Sep 30     DOI: https://doi.org/10.3340/jkns.2015.58.3.205
Citations to this article as recorded by Crossref logo
Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy
A. V. Tallet, F. Dhermain, E. Le Rhun, G. Noël, Y. M. Kirova
Annals of Oncology.2017;[Epub]     CrossRef
SBRT for oligoprogressive oncogene addicted NSCLC
L. Basler, S.G.C. Kroeze, M. Guckenberger
Lung Cancer.2017; 106: 50.     CrossRef
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review
Stephanie G.C. Kroeze, Corinna Fritz, Morten Hoyer, Simon S. Lo, Umberto Ricardi, Arjun Sahgal, Rolf Stahel, Roger Stupp, Matthias Guckenberger
Cancer Treatment Reviews.2017; 53: 25.     CrossRef
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
Wen-Chi Yang, Furen Xiao, Jin-Yuan Shih, Chao-Chi Ho, Ya-Fang Chen, Ham-Min Tseng, Kuan-Yu Chen, Wei-Yu Liao, Chong-Jen Yu, James Chih-Hsin Yang, Sung-Hsin Kuo, Jason Chia-Hsien Cheng, Pan-Chyr Yang, Feng-Ming Hsu
Radiotherapy and Oncology.2017;[Epub]     CrossRef
Surgery in oligometastatic NSCLC patients in the targeted therapy era
Qi Zhang, Yi-Long Wu
Lung Cancer Management.2016; 5(3): 141.     CrossRef